NTRK1基因融合在幼年性黄色肉芽肿中频繁出现
本研究在一例先天性幼年性黄色肉芽肿(JXG)患儿中通过二代测序发现TPM3::NTRK1基因融合,并对34例非朗格汉斯细胞组织细胞增生症进行回顾性分析,额外发现4例JXG和1例成人黄色肉芽肿存在NTRK1基因融合。结论提示NTRK1基因融合在JXG中中度常见(本系列6/21,28.6%),建议对难治性JXG进行NTRK基因融合检测,NTRK抑制剂可能成为新的治疗选择。
要点
- NTRK1基因融合在JXG中占28.6%(6/21),发生频率较高。
- 对难治性JXG应考虑将NTRK基因融合纳入基因检测panel。
- NTRK抑制剂可能为临床病程棘手的JXG提供新的有效治疗。
核心结论
- NTRK1基因融合在JXG中中度常见,本系列发生率为28.6%(6/21)。
- JXG属于NTRK基因重排频率最高的增殖性疾病之一。
- NTRK抑制剂可能成为难治性JXG的新型有效治疗。
研究设计与样本
- 病例报告:一例早产双胎新生儿先天性JXG,表现为胸部皮下浸润、肝脾肿大、腹水、全血细胞减少及腹部和四肢瘀点。
- 对皮下浸润组织行二代测序,发现TPM3::NTRK1基因融合。
- 回顾性分析34例非朗格汉斯细胞组织细胞增生症(16例JXG、3例成人黄色肉芽肿、1例良性头部组织细胞增生症、13例Rosai-Dorfman病、1例Erdheim-Chester病)的NTRK1、2、3异常。
主要发现
- 回顾性分析额外发现4例JXG和1例成人黄色肉芽肿存在NTRK1基因融合。
- 结合病例报告,本系列JXG中NTRK1基因融合总发生率为6/21(28.6%)。
关键数值与推荐
- 本系列JXG中NTRK1基因融合发生率为6/21(28.6%)。
临床怎么用
- 对难治性JXG,基因检测panel应包含NTRK基因融合。
- NTRK基因融合可作为JXG的潜在治疗靶点,NTRK抑制剂可能用于临床病程棘手的JXG。
局限性
- 回顾性分析样本量有限(34例非朗格汉斯细胞组织细胞增生症)。
- 病例报告仅描述单例先天性JXG。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Juvenile Xanthogranuloma (JXG) is a rare form of non-Langerhans cell histiocytosis. The most common known gene mutations affect the mitogen-activated protein (MAP) kinase, phosphoinositide 3-kinase (PI3K), and Janus kinase/signal transducer and activator of transcription ( JAK / STAT ) signaling pathways. We present a case of congenital JXG in a premature newborn from a dicygotic twin pregnancy with subdermal infiltrates on the chest, hepatosplenomegaly, ascites, pancytopenia, and petechiae on the abdomen and extremities. Next-generation sequencing of tissue from a subdermal infiltrate revealed a tropomyosin 3::neurotrophic tyrosine kinase receptor ( TPM3 :: NTRK1 ) gene fusion. Therefore, a retrospective analysis of 34 additional non-Langerhans cell histiocytoses (16 JXG, 3 adult xanthogranuloma and 1 benign cephalic histiocytosis, both clinical subtypes of JXG, as well as 13 Rosai-Dorfman and 1 Erdheim-Chester disease) for NTRK 1, 2 and 3 aberrations was performed. This analysis revealed an NTRK1 gene fusion in 4 additional JXGs and 1 adult xanthogranuloma. In conclusion, NTRK1 gene fusions are moderately common in JXG (6/21; 28.6% in our series). This finding places JXG in the category of proliferative diseases with one of the highest frequencies of NTRK gene rearrangements. Therefore, NTRK gene fusions should be included in a gene panel test for difficult-to-treat JXG. Given the potential of NTRK gene fusions as a therapeutic target, NTRK inhibitors may represent a novel effective treatment for JXG with a challenging clinical course.
引用
- Schlögl E, Hürner-Unterberger H, Simonitsch-Klupp I, et al. NTRK1 Gene Fusions Are Frequent in Juvenile Xanthogranuloma. Am J Surg Pathol. 2025. PMID: 40235191. doi:10.1097/PAS.0000000000002405
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。